42 results about "C2C12" patented technology

The present invention provides methods of improving the osteogenic and / or chondrogenic activity of a bone matrix, e.g., a dermineralized bone matrix (DBM), by exposing the bone matrix to one or more treatments or conditions. In preferred embodiments the bone matrix is derived from human bone. The treatment or condition may alter the structure of the bone matrix and / or cleave one or more specific proteins. Cleavage may generate peptides or protein fragments that have osteoinductive, osteogenic, or chondrogenic activity. Preferred treatments include collagenase and various other proteases. The invention further provides improved bone and cartilage matrix compositions that have been prepared according to the inventive methods and methods of treatment using the compositions. The invention further provides methods of preparing, testing, and using the improved bone matrix compositions. On a assay comprises exposing relatively undifferentiated mesenchymal cells to a bone matrix composition and measuring expression of a marker characteristic of osteoblast or chondrocyte lineage(s). Increased expression of the marker relative to the level of the marker in cells that have been exposed to a control matrix (e.g., an inactivated or untreated matrix) indicates that the treatment or condition increased the osteogenic and / or chondrogenic activity of the bone matrix. Suitable cells include C2C12 cells. A suitable marker is alkaline phosphatase. The inventive methods increase the osteogenic and / or chondrogenic activity of human DBM when tested using this assay system.

The method of the invention provides for producing a heterologous protein in mammalian host cells having nucleic acid encoding Hepatitis B X protein and the heterologous protein, by growing mammalian host cells selected from the group consisting of HKB11, CHO, BHK21, C2C12, and HEK293 cells, by growing mammalian host cells in non-adherent suspension culture, or by growing mammalian host cells which contain nucleic acid providing exogenous X-box Binding Protein, XBP1s. The conditions should be such that HBx, exogenous XBP1s if present, and the heterologous protein are expressed by the mammalian cells. The invention includes compositions for carrying out the method.

The invention belongs to differentiation culture of myoblasts, and relates to a differentiation culture method of C2C12 myoblasts. Separated mouse myoblasts sub-cultured more than five times are used as objects, a growth medium and a differentiation medium are optimized through steps of cell proliferation culture, differentiation culture and the like, and over 85% of the myoblasts sub-cultured more than five times can differentiate myotubes, thus effectively improving the utilization ratio of the separated primary myoblasts.

The invention provides a solution for preserving magnetosome and an application thereof and belongs to the application field of biomaterials. The solution for preserving magnetosome is a phosphatic buffer solution (PBS). During the process of preserving magnetosome, the structure and functions of magnetosome are the least influenced and interfered by the solution. A BMPs-PEI / DNA composite obtained by connection of preserved magnetosome can reach higher PEI, nucleic acid fragments immobilization and ligation efficiency. By the adoption of the solution, cell transfection ratios of Hela, Hep-G2, Cos-7 and C2C12 are respectively higher than cell transfection ratio of magnetosome preserved by a routine method. The BMPs preserving solution provided by the invention is of great practical significance for more efficiently preserving BMPs for longer and more widely performing its application value.

The invention provides the application of transcription factor MyoD in regulating the expression of pig RTL1 gene. Taking RTL1 as the research object, by constructing the recombinant plasmid of porcine RTL1 gene promoter dual luciferase reporter gene, and finding the core promoter region of RTL1; verifying the interaction between the transcription factor MyoD and the core promoter region of RTL1; then constructing MyoD overexpression vector and synthetic small interfering RNA were used to detect the effect of MyoD on RTL1; the transcription factor MyoD binding site mutant fluorescent expression vector MyoD‑mut was also constructed to detect luciferase activity after transfection into PK15 and C2C12 cells. The invention confirms the influence of transcription factor MyoD on RTL1 gene transcriptional regulation for the first time, brings a deeper level of cognition to the expression regulation of RTL1, and has a good application prospect in the improvement of livestock meat quality traits and the molecular regulation mechanism of muscle development .

The invention relates to applications of dibenzyl citrate in inhibition of calcium ion deposition diseases, and belongs to the technical field of chemical biology. Experimental data of the present invention show that the dibenzyl citrate has effects of good mouse myoblast C2C12 calcification inhibition and effective reduction of calcium ion concentration in human skeletal muscle cell HSK, and after cavia porcellus with arthritis is selected as the animal model and the dibenzyl citrate is used to treat, the bone joint density photo of the cavia porcellus obviously becomes clear.